Abiratas 250mg Tablet

Abiratas 250mg Tablet is an anti-cancer medicine used to treat metastatic castration-resistant prostate cancer (mCRPC). It contains Abiraterone acetate. It is a type of drug known as an androgen biosynthesis inhibitor, which works by preventing the production of androgens (male hormones like testosterone) that promote the growth of prostate cancer cells.

Uses of Abiratas 250mg Tablet

• Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• Metastatic High-Risk Castration-Sensitive Prostate Cancer (mCSPC)

How does the Abiratas 250mg Tablet work?

It inhibits the action of the CYP17A1 enzyme that is needed to produce androgens (testosterone) in the adrenal glands, testes, and prostate tumour tissues. Blocking this enzyme drastically lowers androgen levels, starving prostate cancer cells of the hormones they need to grow. It is especially effective in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

How to Use This Medication?

Take this medication by mouth on an empty stomach once daily, 2 hours before or 1 hour after a meal. Do not chew or crush the tablets. Swallow the tablets whole to help avoid additional adverse effects.

Your dose is based on your medical condition, laboratory tests, response to treatment, and any other medications you are taking. Make sure your doctor and pharmacist know about all the products you use.

Taking this medicine daily provides the maximum benefit. Take it at the same time each day to help you remember. Do not stop taking your prostate cancer medication unless instructed by your doctor, as stopping treatment may allow the cancer to progress more quickly.

Possible Side Effects

• Swelling
• Hypokalemia (low potassium)
• Hypertension (high blood pressure)
• Elevated liver enzymes
• Fatigue
• Joint pain
• Nausea
• Vomiting
• Anemia
• Diarrhea

Safety Advise

🩺 Kidney

Abiratas 250mg Tablets should be used with caution in patients with severe renal disease. The dose may need to be adjusted. Please talk to your healthcare provider.

⚠️ Liver

Abiratas 250mg Tablets should be used with caution in patients with severe liver disease. The dose may need to be adjusted. Please speak with your healthcare provider.

🤰 Pregnancy

Abiratas Tablets are not recommended for use during pregnancy due to the risk of foetal harm. Please consult your healthcare provider.

🤱 Breastfeeding

Abiratas 250mg Tablet is not recommended while breastfeeding. Evidence suggests that the medicine may be harmful. Please consult your healthcare provider.

🍷 Alcohol

It is not known whether it is safe to consume alcohol while taking Abiratas 250mg Tablets. Please discuss this with your healthcare provider.

Storage Instructions

Store in a cool, dry place below 30°C and protect from moisture.

References

• Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers.
• Katzung BG, Vanderah TW. Basic and Clinical Pharmacology. 15th ed. New York: McGraw Hill.
• Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology. 2008;26(28):4563-4571.
• Auchus RJ, Yu MK, Nguyen S, Mundle SD. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. The Oncologist. 2014;19(12):1231-1240.
• Janssen Biotech, Inc. Zytiga (Abiraterone Acetate) Tablets Prescribing Information. U.S. Food and Drug Administration.

Disclaimer

IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.